SCHEMBL4958411

SCHEMBL4958411

CC(C)(C)OC(=O)Cc1ccc(C(=O)Nc2nc3c(s2)Cc2cc(F)ccc2-3)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 18/20 0.57
TP53 P04637 8/20 0.57
SMN1; SMN2 Q16637 8/20 0.57
ALDH1A1 P00352 7/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
APAF1 O14727 4/20 0.57
CYP1A2 P05177 3/20 0.57
CYP3A4 P08684 3/20 0.57
CYP2C9 P11712 3/20 0.57
CYP2C19 P33261 3/20 0.57
TDP2 O95551 2/20 0.57
BLM P54132 2/20 0.57
CASP3 P42574 1/20 0.57
MCL1 Q07820 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957199 0.77 MAPT (0.61) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL4963945 0.75 MAPT (0.60) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL4958725 0.74 ADORA1 (0.60) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL8666248 0.70 MAPT (0.64) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL8671673 0.70 MAPT (0.63) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL4958817 0.69 MAPT (0.52) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL4960364 0.69 MAPT (0.73) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL8666934 0.68 ADORA1 (0.55) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL4957609 0.67 ADORA1 (0.66) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL8665878 0.67 MAPT (0.54) MAPTTP53SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407977-B2 Substituted N-acyl-2-aminothiazoles HOFFMAN-LA ROCHE INC. (US) 2008-08-05 US disclosed
EP-1791822-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-06 EP disclosed
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles HOFFMANN-LA ROCHE INC. 2006-02-09 US disclosed
WO-2006013054-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles SLC5A2, ABAT, AGTR2 MAPT 1360/4885TP53 4777/4885SMN1; SMN2 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.